First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Subscribe To Our Newsletter & Stay Updated
